(Reuters) - Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim ... sales would reduce his price target on the company's stock to $7 from $24. Celldex, which is …
Among the sector stocks, Idera Pharmaceuticals (NASDAQ: IDRA) was down more than 21 percent, while Celldex
NCR Corp., $1.10 to $25.78 The ATM maker raised its annual profit estimate after saying it will buy back $250 million in company stock. The taco chain’s profit forecasts came up short of Wall Street estimates. Celldex Therapeutics Inc., …
Mr. Sam Martin is Chief Financial Officer, Senior Vice President of the Company effective July 1, 2017. Mr. Martin joined Celldex in April 2009 and currently serves as Vice President, Finance. Mr. Martin joined Celldex as the Director of …
NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the …
CELLDEX THERAPEUTICS INC, $15.34 ... 7.61 pct At least two brokerages cut their price targets on the video game publisher’s stock, after it reported a fall in fourth-quarter profit and revenue on Tuesday. The company forecast fiscal …
Pfizer has decided to terminate a brain cancer vaccine partnership with Celldex Therapeutics ... Investors have been less enthusiastic and the company's stock sank 26.2% to $3.53.
The "Ewing Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, …
A late-stage study for a brain cancer vaccine has been discontinued, Celldex Therapeutics Inc. announced Monday. The drug manufacturing company said the results from a preplanned independent analysis found that the vaccine, Rintega, …